

Tuberculosis Epidemiology and its Diagnostic Modality
Abstract
References
WHO Report, 2022
Central TB division, TB Report 2023
Implementing the WHO Stop TB Strategy: A Handbook for National Tuberculosis Control Programmes.
Mangayarkarasi V, Kalaiselvi K, Kavitha DM, Chitraleka V, Balaji R. Program Based Teaching and Learning (PBTL) to increase the competency level in Undergraduate medical students with a model of Revised National Tuberculosis control program (RNTCP), Journal of Microbiology and Biology Education (American Society of Microbiology Journals).
Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013:828939. doi: 10.1155/2013/828939
Kalaiselvi, K., .Mangayarkarasi V, Shivshankar R.M and Raja Shunmugam, Siva Kumar S, Uma Devi KR, 'Enhancing antimycobacterial activity of Isoniazid and Rifampicin incorporated Norbornene nanoparticles', International Journal of Mycobacteriology 2018 Jan-Mar;7(1):84-88. doi: 10.4103/ijmy.ijmy_162_17.
Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, Arbex MA, Augusto VM, Rabahi MF, Mello FCQ. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018 Apr;44(2):145-152. doi: 10.1590/s1806-37562017000000443. PMID: 2979155.
Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9)
Chaisson RE, Frick M, Nahid P. The scientific response to TB - the other deadly global health emergency. Int J Tuberc Lung Dis. 2022 Mar 1;26(3):186-189. doi: 10.5588/ijtld.21.0734. PMID: 35197158; PMCID: PMC8886961.
https://www.who.int/news-room/fact-sheets/detail/millennium-development-goals-(mdgs)
Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863. doi: 10.1101
Ranganath R, Kumar VG, Ranganath R, Goud G, Javali V. Drug Resistance Pattern of MTB Isolates from PTB Patients. Tuberc Res Treat. 2013;2013:862530. doi: 10.1155/2013/862530.
Kalaiselvi, K., Mangayarkarasi V, Gomathi N.S., Shivshankar R.M and Raja Shunmugam. 2016. Antimycobacterial Activity of Norbornene-Polyethylene Glycol, Isoniazid and Rifampicin Nanocarrier towards Mycobacterium tuberculosis. International Journal of Current Microbiology and Applied Sciences. 5 (8): 394-401.
Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, Arbex MA, Augusto VM, Rabahi MF, Mello FCQ. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018 Apr;44(2):145-152. doi: 10.1590/s1806-37562017000000443. PMID: 2979
Magee MJ, Salindri AD, Gujral UP, Auld SC, Bao J, Haw JS, Lin HH, Kornfeld H. Convergence of non-communicable diseases and tuberculosis: a two-way street? Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1258-1268. doi: 10.5588/
Kalaiselvi, K., Mangayarkarasi V, Gomathi N.S., Balaji S, Shivshankar R.M and Raja Shunmugam.2017 Luciferase phage reporter assay for drug susceptibility testing for Norbornene based Nano anti-TB drugs. Asian Journal of Pharmaceutical and Clinical Sciences, 10(9),1-3ISSN 1473-309
https://www.who.int/news-room/fact-sheets/detail/tuberculosis
stevenson, C.R., Forouhi, N.G., Roglic, G. et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234 (2007). https://doi.org/10.1186/1471-2458-7-234.
Mahishale V, Angadi N, Metgudmath V, Eti A, Lolly M, Khan S. Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study. J Transl Int Med. 2015 Oct-Dec;3(4):155-160. doi: 10.1515/jtim-2015-0019. Epub 2015 Dec 30
Tiamiyu AB, Iliyasu G, Dayyab FM, Habib ZG, Tambuwal SH, Animashaun AO, Galadanci H, Bwala SA, Lawson L, Habib AG. A descriptive study of smear negative pulmonary tuberculosis in a high HIV burden patient's population in North CentreNigeria. PLoS One. 2020 Sep 1;15(9):e0238007.
Tsara V, Serasli E, Christaki P. Problems in diagnosis and treatment of tuberculosis infection. Hippokratia. 2009 Jan;13(1):20-2. PMID: 19240816; PMCID: PMC2633248.
Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004 Jun;4(6):337-48. doi: 10.1016/S1473-3099(04)01044-8.
Thomsen VO, Kok-Jensen A, Buser M, Philippi-Schulz S, Burkardt HJ. Monitoring treatment of patients with pulmonary tuberculosis: can PCR be applied? J Clin Microbiol. 1999 Nov;37(11):3601-7. doi: 10.1128/JCM.37.11.3601-3607.1999.
Torres MJ, Criado A, Palomares JC, Aznar J. Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol. 2000 Sep;38(9):3194-9. doi: 10.1128/JCM.38.9.3194-3199.2000.
DOI: https://doi.org/10.37591/rrjomv.v13i3.3390
Refbacks
- There are currently no refbacks.